CN-119081922-B - Lactobacillus gasseri strain A21120 with antioxidant, anti-inflammatory and anti-tumor functions, and probiotic agent and application thereof

Abstract

The invention provides a lactobacillus gasseri (Lactobacillus gasseri) strain A21120 with antioxidant, anti-inflammatory and anti-tumor functions, a probiotic agent and application thereof, and belongs to the technical field of functional microorganisms. The strain A21120 is obtained by separating and screening intestinal faeces of the century old, and belongs to Lactobacillus gasseri through morphological identification and molecular identification. The strain has good gastric juice and bovine choline resistance and intestinal tract colonization potential. The lactobacillus gasseri strain A21120 provided by the invention has antibacterial, anti-inflammatory, antioxidant and antitumor activities, and provides a new way for the treatment and drug development of clinical related diseases and the preparation of in vitro preparations or daily necessities.

Inventors

• YIN MENG
• LUO WEIFEI
• Gan Caiyu
• LU JINMEI
• LU LIANGHUA
• CHAI ZHIHUI

Assignees

• 广西科学院
• 广西爱生生命科技有限公司

Dates

Publication Date

20260512

Application Date

20240820

Claims (8)

1. 1. A Lactobacillus gasseri (Lactobacillus gasseri) strain A21120 is characterized in that the collection unit is the collection of microorganism strains from Guangdong province, and the collection number is GDMCC No:64676.
2. 2. A probiotic, characterized in that the active ingredient comprises lactobacillus gasseri strain a21120 according to claim 1.
3. 3. The probiotic according to claim 2, characterized in that the effective viable count of lactobacillus gasseri strain a21120 is 1 x 10 9 CFU/mg～1×10 11 CFU/mg or 1 x 10 9 CFU/mL～1×10 11 CFU/mL.
4. 4. A probiotic according to claim 2 or 3, characterized in that the formulation of said probiotic comprises at least one of tablets, drops, capsules and powders.
5. 5. The application of the lactobacillus gasseri strain A21120 according to claim 1 or the probiotic agent according to any one of claims 2 to 4 in preparing antitumor drugs, The tumor is colon cancer and/or melanoma; the lactobacillus gasseri strain a21120 is a living thallus.
6. 6. Use of lactobacillus gasseri strain a21120 according to claim 1 for the manufacture of a medicament for at least one of anti-inflammatory, antioxidant and inhibitory pathogenic bacteria, said pathogenic bacteria being e.
7. 7. The use according to claim 6, wherein the anti-inflammatory effect is in inhibiting the expression of a pro-inflammatory factor; the pro-inflammatory factors include IL-6 and/or TNF-alpha.
8. 8. The method according to claim 6, wherein the antioxidant is expressed in terms of increasing the clearance of DPPH, hydroxyl radicals and superoxide anions.

Description

Lactobacillus gasseri strain A21120 with antioxidant, anti-inflammatory and anti-tumor functions, and probiotic agent and application thereof Technical Field The invention belongs to the technical field of functional microorganisms, and particularly relates to a lactobacillus gasseri (Lactobacillus gasseri) strain A21120 with antioxidant, anti-inflammatory and anti-tumor functions, and a probiotic agent and application thereof. Background Lactobacillus gasseri is a type of probiotic bacteria useful in food products that can colonize the human intestinal tract and produce beneficial effects to the host by altering the host flora composition. Timely supplementation of probiotics in the diet is of exceptional importance for people presenting with associated symptoms or diseases. At present, intestinal microorganisms play a non-negligible role in life of people, can maintain intestinal health, and can regulate and control various signal paths through metabolites, so that the intestinal microorganisms are closely related to various diseases. For example, lactobacillus symbiotic with human intestinal tracts is a beneficial bacterium, and plays an important role in inhibiting invasion of pathogenic bacteria, relieving intestinal inflammation and injury, delaying aging and even resisting the development and the development of tumors. The patent with publication number CN117363524A discloses a lactobacillus gasseri MY4 strain which has the effects of resisting oxidation, whitening and delaying aging. Publication No. CN111518724A discloses a Lactobacillus gasseri HMV18, and the protein of the strain has antibacterial and antitumor effects, and can be used for preparing antibacterial and antitumor products. Therefore, the probiotics have potential application value and broad market prospect. However, there is no report on lactobacillus gasseri having both antioxidant, anti-inflammatory and anti-tumor functions. Disclosure of Invention Accordingly, the present invention is directed to a novel lactobacillus gasseri a21120 having antioxidant, anti-inflammatory and anti-tumor functions. The invention provides a lactobacillus gasseri (Lactobacillus gasseri) strain A21120 with a preservation number of GDMCC No:64676. The invention provides a probiotic agent, and an active ingredient comprises the lactobacillus gasseri strain A21120. Preferably, the effective viable count of the Lactobacillus gasseri strain A21120 is 1×10 9CFU/mg~1×1011 CFU/mg or 1×10 9CFU/mL~1×1011 CFU/mL. Preferably, the probiotic is in a dosage form comprising at least one of tablets, drops, capsules and powders. The invention provides application of the lactobacillus gasseri strain A21120 or the probiotic agent in preparing medicines with at least one of anti-tumor, anti-inflammatory, anti-oxidation and anti-pathogenic bacteria effects. Preferably, the tumor or cancer type in the anti-tumor comprises colon cancer and/or melanoma. Preferably, the lactobacillus gasseri strain a21120 comprises live bacteria and inactivated bacteria. Preferably, the anti-inflammatory effect is exhibited by inhibiting the expression of a pro-inflammatory factor; the pro-inflammatory factors include IL-6 and/or TNF-alpha. Preferably, the antioxidant is present in terms of increasing the clearance of DPPH, hydroxyl radicals and superoxide anions. Preferably, the pathogenic bacteria of the pathogenic bacteria inhibition include escherichia coli. The invention provides a Lactobacillus gasseri) strain A21120 with a preservation number of GDMCC No:64676. The strain A21120 is obtained by separating and screening intestinal faeces of the century old, and belongs to Lactobacillus gasseri (Lactobacillus gasseri) through morphological identification and molecular identification. The strain has good gastrointestinal fluid and bovine choline resistance through detection. Meanwhile, the in vitro detection result shows that the strain A21120 has good effect of inhibiting the growth of intestinal pathogenic bacteria, is stronger than the control strain CICC 24878, and has better clearance rate of DPPH, hydroxyl free radicals and superoxide anions than the control strain CICC 24878 and good oxidation resistance. An anti-inflammatory experiment is carried out by taking a Lipopolysaccharide (LPS) -induced mouse mononuclear macrophage line RAW264.7 cell as an in-vitro inflammatory cell model, and the result shows that compared with a model group, the strain A21120 can obviously reduce the expression of pro-inflammatory factors IL-6 and TNF-alpha, and has the anti-inflammatory effect equivalent to that of a commercial strain LGG of a control group. The in vitro anti-tumor experiment result shows that the live bacteria or the inactivated bacteria of the strain A21120 have the effect of inhibiting the proliferation of colon cancer cells and melanoma cells, and the inhibition activity is equivalent to the anti-tumor activity of the commercial strain LGG of the control group. Therefore, the lactobaci